Are you interested in the health care sector? Health care is generally considered a growth sector, mainly because it includes biotech, but it also has companies that exhibit value characteristics such as large dividends.
To dig deeper into the health care sector, we ran a screen. We began by screening health care stocks for those that appear undervalued to earnings growth, with PEG below 1.
We then screened for those with the confidence of institutional investors, with significant net institutional purchases over the last quarter. This indicates that on average institutional investors such as hedge fund managers expect these names to outperform.
Business section: Investing ideas
The final list of stocks from this screen are below. These health care companies appear undervalued, and they have seen optimism from smart investors over the last quarter.
Do you think they'll outperform like hedge fund managers expect?
Use this list as a starting point for your own analysis. (Click here to access free, interactive tools to analyze these ideas.)
2. CIGNA: Operates as a health service organization. Market cap of $13.62 billion. Stock price of $47.54. PEG at 0.96. Net institutional purchases in the current quarter are at 18.2 million shares, which represents about 6.37% of the company's float of 285.67 million shares.
3. Cumberland Pharmaceuticals: Engages in the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets. Market cap of $149.57 million. Stock price of $7.54. PEG at 0.92. Net institutional purchases in the current quarter at 437,000 shares, which represents about 3.35% of the company's float of 13.03 million shares.
6. PDL BioPharma: Engages in the management of antibody humanization patents and royalty assets. Market cap of $843.48 million. Stock price of $6.19. PEG at 0.37. Net institutional purchases in the current quarter at 10.6 million shares, which represents about 8.8% of the company's float of 120.43 million shares.
8. Providence Service: Provides and manages government sponsored social services and non-emergency transportation services. Market cap of $186.69 million. Stock price of $14.47. PEG at 0.9. Net institutional purchases in the current quarter at 418,100 shares, which represents about 3.32% of the company's float of 12.58 million shares.
9. Pernix Therapeutics Holdings: Engages in the development, marketing, and sale of branded and generic pharmaceutical products primarily for the pediatric market. Market cap of $227.76 million. Stock price of $8.84. PEG at 0.58. Net institutional purchases in the current quarter at 635,800 shares, which represents about 32.94% of the company's float of 1.93 million shares.
10. Questcor Pharmaceuticals
11. Sun Healthcare Group: Provides health care services primarily for senior population in the United States. Market cap of $469.00 million. Stock price of $6.55. PEG at 0.69. Net institutional purchases in the current quarter at 1.1 million shares, which represents about 5.54% of the company's float of 19.85 million shares.
12. Transcend Services: Provides medical transcription services in the United States. Market cap of $314.79 million. Stock price of $29.45. PEG at 0.98. Net institutional purchases in the current quarter at 584,700 shares, which represents about 6.25% of the company's float of 9.36 million shares.
13. USANA Health Sciences: Develops, manufactures, distributes, and sells nutritional and personal care products worldwide. Market cap of $544.29 million. Share price of $35.84. PEG at 0.7. Net institutional purchases in the current quarter at 421,800 shares, which represents about 6.1% of the company's float of 6.92 million shares.
Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned above. Analyst ratings sourced from Zacks Investment Research.
Kapitall's Alexander Crawford does not own any of the shares mentioned above. Institutional data sourced from Fidelity. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Shareholders OK Perrigo Acquisition of Elan
Each Elan shareholder is slated to receive $6.25 in cash and 0.07636 shares in New Perrigo for each Elan share.
You’re a Bad Investor. Here’s How to Get Better.
The chances are good that you’re a bad investor. If you have any doubt, compare your performance against that of the S&P 500. One Fool did, and it was humbling.
Perrigo to Buy Elan for $8.6 Billion
Outbids investment firm Royalty Pharma, which unsuccessfully pursued the biotech. Perrigo aims for tax savings.